TY - JOUR
T1 - Pragmatic multicentre factorial randomized controlled trial testing measures to reduce surgical site infection in low- and middle-income countries
T2 - study protocol of the FALCON trial
AU - NIHR Global Health Research Unit on Global Surgery
AU - Ademuyiwa, Adesoji O.
AU - Ghosh, Dhruv
AU - Ramos-De la Medina, Antonio
AU - Moore, Rachel
AU - Ntirenganya, Faustin
AU - Tabiri, Stephen
AU - Chakrabortee, Sohini
AU - Glasbey, James
AU - Lillywhite, Rachel
AU - Magill, Laura
AU - Monahan, Mark
AU - Omar, Omar
AU - Hardy, Pollyanna
AU - Brocklehurst, Peter
AU - Morton, Dion
AU - Bhangu, Aneel
AU - Runigamugabo, Emmy
AU - Verjee, Azmina
AU - Adisa, Adewale O.
AU - Aguilera, Maria Lorena
AU - Alexander, Philip
AU - Haque, Parvez David
AU - Harrison, Ewen
AU - Ingabire, Jean De La Croix Allen
AU - Ismail, Lawani
AU - Salem, Hosni Khairy
AU - Kroese, Karolin
AU - Lapitan, Marie Carmela
AU - Lissauer, David
AU - Pinkney, Thomas
AU - Qureshi, Ahmad Uzair
AU - Roberts, Tracy
AU - Winkles, Neil
N1 - © 2020 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.
PY - 2020/9/13
Y1 - 2020/9/13
N2 - AIM: Surgical site infection (SSI) is the commonest postoperative complication worldwide, representing a major burden for patients and health systems. Rates of SSI are significantly higher in low- and middle-income countries (LMICs) but there is little high-quality evidence on interventions to prevent SSI in LMICs.METHOD: FALCON is a pragmatic, multicentre, 2 x 2 factorial, stratified randomized controlled trial, with an internal feasibility study, which will address the need for evidence on measures to reduce rates of SSI in patients in LMICs undergoing abdominal surgery. To assess whether either (1) 2% alcoholic chlorhexidine versus 10% povidone-iodine for skin preparation, or (2) triclosan-coated suture versus non-coated suture for fascial closure, can reduce surgical site infection at 30-days post-surgery for each of (1) clean-contaminated and (2) contaminated/dirty surgery. Patients with predicted clean-contaminated or contaminated/dirty wounds with abdominal skin incision ≥ 5 cm will be randomized 1:1:1:1 between (1) 2% alcoholic chlorhexidine and noncoated suture, (2) 2% alcoholic chlorhexidine and triclosan-coated suture, (3) 10% aqueous povidone-iodine and noncoated suture and (4) 10% aqueous povidone-iodine and triclosan-coated suture. The two strata (clean-contaminated versus contaminated/dirty wounds) are separately powered. Overall, FALCON aims to recruit 5480 patients. The primary outcome is SSI at 30 days, based on the Centers for Disease Control definition of SSI.CONCLUSION: FALCON will deliver high-quality evidence that is generalizable across a range of LMIC settings. It will influence revisions to international clinical guidelines, ensuring the global dissemination of its findings.
AB - AIM: Surgical site infection (SSI) is the commonest postoperative complication worldwide, representing a major burden for patients and health systems. Rates of SSI are significantly higher in low- and middle-income countries (LMICs) but there is little high-quality evidence on interventions to prevent SSI in LMICs.METHOD: FALCON is a pragmatic, multicentre, 2 x 2 factorial, stratified randomized controlled trial, with an internal feasibility study, which will address the need for evidence on measures to reduce rates of SSI in patients in LMICs undergoing abdominal surgery. To assess whether either (1) 2% alcoholic chlorhexidine versus 10% povidone-iodine for skin preparation, or (2) triclosan-coated suture versus non-coated suture for fascial closure, can reduce surgical site infection at 30-days post-surgery for each of (1) clean-contaminated and (2) contaminated/dirty surgery. Patients with predicted clean-contaminated or contaminated/dirty wounds with abdominal skin incision ≥ 5 cm will be randomized 1:1:1:1 between (1) 2% alcoholic chlorhexidine and noncoated suture, (2) 2% alcoholic chlorhexidine and triclosan-coated suture, (3) 10% aqueous povidone-iodine and noncoated suture and (4) 10% aqueous povidone-iodine and triclosan-coated suture. The two strata (clean-contaminated versus contaminated/dirty wounds) are separately powered. Overall, FALCON aims to recruit 5480 patients. The primary outcome is SSI at 30 days, based on the Centers for Disease Control definition of SSI.CONCLUSION: FALCON will deliver high-quality evidence that is generalizable across a range of LMIC settings. It will influence revisions to international clinical guidelines, ensuring the global dissemination of its findings.
KW - randomized controlled trial
KW - surgery
KW - surgical site infection
KW - wound infection
UR - http://www.scopus.com/inward/record.url?scp=85092132515&partnerID=8YFLogxK
U2 - 10.1111/codi.15354
DO - 10.1111/codi.15354
M3 - Article
C2 - 32920941
SN - 1462-8910
JO - Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland
JF - Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland
ER -